Free tool
FAERS Monitor: Kalydeco
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207925 or its brand name (Kalydeco, Ivacaftor). Reports on generic versions are filed under their own applications.
Reports
7,984
Serious
5,947
74% of reports
Hospitalization
4,426
Death reported
327
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hospitalisation1,384
- infective pulmonary exacerbation of cystic fibrosis611
- pneumonia271
- infection257
- lower respiratory tract infection255
- malaise255
- death229
- cough225
- cystic fibrosis220
- headache197
- nasopharyngitis171
- influenza162
- dyspnoea145
- pulmonary function test decreased138
- off label use126
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 174 |
| 2013 | 129 |
| 2014 | 383 |
| 2015 | 523 |
| 2016 | 271 |
| 2017 | 403 |
| 2018 | 558 |
| 2019 | 1,037 |
| 2020 | 896 |
| 2021 | 593 |
| 2022 | 651 |
| 2023 | 598 |
| 2024 | 750 |
| 2025 | 695 |
| 2026 | 323 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,175 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 611 | 333.0 | 307.0 | 179,302 |
| cystic fibrosisSignal | 220 | 109.0 | 95.4 | 22,503 |
| pulmonary function test decreasedSignal | 138 | 85.7 | 72.5 | 11,111 |
| hospitalisationSignal | 1,384 | 23.9 | 22.8 | 30,342 |
| lower respiratory tract infectionSignal | 255 | 14.9 | 13.2 | 3,269 |
| infectionSignal | 257 | 4.7 | 4.2 | 745 |
| influenzaSignal | 162 | 3.8 | 3.3 | 337 |
| nasopharyngitisSignal | 171 | 2.4 | 2.1 | 146 |
| pneumoniaSignal | 271 | 2.2 | 2.0 | 180 |
| coughSignal | 225 | 2.1 | 1.9 | 133 |
| malaise | 255 | 1.5 | 1.4 | 48 |
| headache | 197 | 0.8 | 0.7 | 7 |
| death | 229 | 0.7 | 0.6 | 30 |
| dyspnoea | 145 | 0.7 | 0.6 | 23 |
| off label use | 126 | 0.4 | 0.3 | 133 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.